UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38977 PHREESIA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-2275479 (State or Other Jurisdiction of Inc ...

Exhibit 99.1 Phreesia Announces Fourth Quarter Fiscal 2024 Results WILMINGTON, Delaware, March 14, 2024 – Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2024. "Phreesia ended fiscal year 2024 with strong momentum going into fiscal 2025. We facilitated more than 150 million patient visits in fiscal 2024, or more than one in ten patient visits across the U.S. We are confident that our solutions and our ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Phreesia (PHR) reports results for the quarter ended January 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on March 14, 2024, might help the stock move higher if these key numbers are better than expect ...

WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia is proud to announce that its Chief Clinical Officer Hilary Hatch, PhD, has been selected to participate in the National Quality Forum (NQF)’s 2024-2025 Leadership Consortium. Dr. Hatch is one of only 29 healthcare leaders included in the prestigious group, underscoring her dedication to healthcare quality and patient-centered care. She was first named to the group for a two-year term in 2022. NQF’s Leadership Consortium is an exclusive forum of experts representi ...

WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, is proud to release data from an analysis of its cancer prevention campaigns illustrating the significant impact its platform can have on increasing rates of cancer screenings. By engaging patients at critical moments in their healthcare journey, Phreesia is driving an effort to ensure that cancer is caught early, at a stage when it can be treated with good health outcomes. The analysis revealed that when patie ...

公司背景 - Phreesia是一家医疗信息系统公司，提供患者登记解决方案[2] 盈利表现 - Phreesia在过去一年中四次超过Zacks Consensus Estimate，平均正收益惊喜为12.2%[4] - Phreesia最近加速了走向盈利的步伐，每个季度的每股亏损都在减少，10月2023季度的每股亏损降至0.58美元，较之前每个季度的减少了10美分[5] - Phreesia的盈利预期修订表明公司正在朝着盈利的方向努力，当前季度的共识预期从0.71美元的亏损移动到0.58美元的亏损，明年的预期也有所改善[7] 估值情况 - Phreesia的估值方面，虽然目前没有盈利，但市销率为4.3倍，运营利润率在过去几个季度持续改善[9]

Phreesia参与国家成人和流感免疫峰会行动号召活动 - Phreesia加入了国家成人和流感免疫峰会的行动号召活动，旨在提高成人接种率[1] 活动使命 - 该活动的使命是鼓励医疗保健提供者采取行动，改善成人疫苗接种建议的实施，以保护成人免受可预防的疾病、残疾和死亡[2] Phreesia的疫苗管理工具 - Phreesia的疫苗管理工具支持医疗机构收集关键信息，与患者讨论免疫接种，并节省工作人员时间[4]

WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, is proud to announce that Audrey Gato, Vice President of Client Solutions, has been named to The Software Report’s list of the Top 50 Women Leaders in SaaS of 2023. Honorees were chosen based on their leadership and contributions to the Software-as-a-Service industry. This is the sixth consecutive year a female leader from Phreesia has been named to the list. Previous Phreesia awardees include Allison Hoffman, ...

Post-Script Engagement - Phreesia的新药物依从性解决方案Post-Script Engagement被行业贸易出版物PM360评为2023年最具创新营销技术或服务之一[1] - Post-Script Engagement能够在患者处方开具后立即为患者提供资源，帮助他们遵守药物使用，无论是首次还是补充处方[3] - Post-Script Engagement调查衡量患者填写处方的可能性，帮助医生根据调查结果定制与患者的互动，以解决他们独特的依从性挑战[5]

公司财务表现 - 2023年10月31日，公司总收入同比增长25%，达到9,160万美元[143] - 2023年10月31日，公司净亏损为3,190万美元，较去年同期净亏损40,200万美元有所减少[143] - 2023年10月31日，调整后的EBITDA为负6,600万美元，较去年同期负18,300万美元有所改善[143] - 2023年10月31日，公司现金及现金等价物为1.034亿美元，较今年1月31日减少7,330万美元[144] 收入来源 - 公司主要通过提供面向医疗行业的集成SaaS软件和支付平台来产生收入[169] - 订阅和相关服务是总收入的主要组成部分，订阅费用主要根据医疗服务客户的数量来计算[170] - 支付处理费用主要根据通过Phreesia平台处理的患者支付量来计算，信用卡和借记卡支付量占总支付量的82%[171] - 网络解决方案主要通过向生命科学和支付方客户提供直接沟通来产生收入[172] 费用支出 - 三个月截至2023年10月31日的成本费用（不包括折旧和摊销）增长了7%[187] - 三个月截至2023年10月31日的销售和营销费用持平，但研发费用增长了26%[192][195] - 研发支出在2023年前九个月增加了1,663.8万美元，达到了82,484万美元，同比增长25%[196] - 总体而言，2023年前九个月的研发支出增加主要是由于员工薪酬和福利成本增加，外部服务成本增加，软件成本增加，硬件和托管成本增加[196] 现金流和财务活动 - 调整后的EBITDA在2023年前九个月为负值，达到了-31,918万美元[211] - 自由现金流在2023年前九个月为负值，达到了-46,533万美元[213] - 公司相信现金和现金等价物以及业务中产生的现金足以支持至少未来12个月的运营[214] - 公司在2023年10月31日的债务受到第三家银行的第一优先权担保，包括财务契约，要求公司保持最低调整后的速动比率，并限制公司在SVB之外持有的现金和现金等价物的金额[217]